Insulet Corporation is trading 5.3% up today at $159.56 as investors react to the U.S. rollout of Omnipod 5 algorithm upgrades and expanded CGM compatibility.
- Shares are rebounding from recent weakness as traders refocus on the company’s product roadmap and recent software enhancements.
- The stock is outperforming a broadly weaker market, aided by positive sentiment and attention from the ADA Scientific Sessions.